Biotech Values

[DewDiligence]

Apexigen goes public via SPAC-merger with BCAC:

https://www.globenewswire.com/news-release/2022/03/18/2405858/0/en/Apexigen-and-Brookline-Capital-Acquisition-Corp-Announce-Business-Combination-Agreement-to-Create-Publicly-Listed-Immuno-oncology-Company.html

Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient’s immune system to combat and eradicate cancer. [Rhetorical: What else would an I-O agent do?]

The deal is expected to close in Jul 2022, and the ticker symbol will become ‘APGN’. The nominal deal value is $205M.